title: Aspirin resistance in atherosclerosis.
abstract: Clinically, aspirin resistance is defined as the failure of aspirin therapy to prevent an acute vascular thrombotic event despite regular intake of appropriate doses. In the laboratory, aspirin resistance encompasses the drug's failure to attain a particular level of platelet inhibition. From a clinical standpoint, the inability of aspirin to prevent a thrombotic event, despite appropriate cyclooxygenase-1 inhibition, implies the involvement of other factors. Evidence is emerging that aspirin resistance, as defined by residual platelet activity, merely reflects an individual's enhanced basal platelet function and suggests a hereditary component. Due to the multifactorial nature of cardiovascular disease, it is likely that a single therapy like aspirin cannot fully treat and prevent all thrombotic complications in the setting of atherosclerosis.
authors.affiliation: Boston University School of Medicine, 700 Albany Street, W507, Boston, MA 02118, USA.
authors.forename: Price
authors.initials: P
authors.lastname: Blair
authors.forename: Jane E
authors.initials: JE
authors.lastname: Freedman
mesh_terms: D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D001792:Blood Platelets / Q000502:physiology; D003324:Coronary Artery Disease / Q000150:complications* / Q000503:physiopathology; D003328:Coronary Thrombosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D015539:Platelet Activation / Q000187:drug effects / Q000235:genetics; D010974:Platelet Aggregation / Q000187:drug effects / Q000235:genetics
chemical_list: D016861:Cyclooxygenase Inhibitors; D001241:Aspirin